NCT07672769: Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes
- State
- Under way
- Phase
- Phase 2
- People
- 90 planned
- Started
- Nov 2026
- Primary completion
- Nov 2027
- Arms
- Bexmarilimab (1mg/kg) and azacitidine, Bexmarilimab (3mg/kg) and azacitidine
- Results
- None posted
- 29 Jun 2026: Trial registered